MA51890A - Peptides et combinaison de peptides d'origine non-canonique destinés à être utilisés en immunothérapie contre différents types de cancers - Google Patents

Peptides et combinaison de peptides d'origine non-canonique destinés à être utilisés en immunothérapie contre différents types de cancers

Info

Publication number
MA51890A
MA51890A MA051890A MA51890A MA51890A MA 51890 A MA51890 A MA 51890A MA 051890 A MA051890 A MA 051890A MA 51890 A MA51890 A MA 51890A MA 51890 A MA51890 A MA 51890A
Authority
MA
Morocco
Prior art keywords
peptides
canonic
cancers
combination
different types
Prior art date
Application number
MA051890A
Other languages
English (en)
Inventor
Jens Fritsche
Franziska Hoffgaard
Daniel Kowalewski
Oliver Schoor
Heiko Schuster
Chih-Chiang Tsou
Toni Weinschenk
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of MA51890A publication Critical patent/MA51890A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001114—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001118—Receptors for colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA051890A 2018-02-21 2019-02-08 Peptides et combinaison de peptides d'origine non-canonique destinés à être utilisés en immunothérapie contre différents types de cancers MA51890A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862633325P 2018-02-21 2018-02-21
DE102018103944 2018-02-21
DE102018107224.4A DE102018107224A1 (de) 2018-02-21 2018-03-27 Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten

Publications (1)

Publication Number Publication Date
MA51890A true MA51890A (fr) 2020-12-30

Family

ID=67482070

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051890A MA51890A (fr) 2018-02-21 2019-02-08 Peptides et combinaison de peptides d'origine non-canonique destinés à être utilisés en immunothérapie contre différents types de cancers

Country Status (22)

Country Link
US (79) US10993962B2 (fr)
EP (2) EP4321529A3 (fr)
JP (4) JP7536642B2 (fr)
KR (2) KR20200116527A (fr)
CN (1) CN114040921A (fr)
AU (5) AU2019225879B2 (fr)
BR (2) BR112020014272A2 (fr)
CA (1) CA3086916A1 (fr)
CL (4) CL2020002123A1 (fr)
CO (1) CO2020009869A2 (fr)
CR (1) CR20200365A (fr)
DE (1) DE102018107224A1 (fr)
EA (2) EA202091833A1 (fr)
IL (2) IL276845A (fr)
MA (1) MA51890A (fr)
MX (2) MX2020007767A (fr)
MY (1) MY200985A (fr)
PE (2) PE20211300A1 (fr)
PH (1) PH12020551295A1 (fr)
SG (2) SG10202010171VA (fr)
TW (3) TWI837747B (fr)
WO (1) WO2019162110A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
MA56036A (fr) 2019-05-27 2022-04-06 Immatics Us Inc Vecteurs viraux et leur utilisation dans une thérapie cellulaire adoptive
US20200384028A1 (en) 2019-06-06 2020-12-10 Immatics Biotechnologies Gmbh Sorting with counter selection using sequence similar peptides
WO2021041920A1 (fr) * 2019-08-28 2021-03-04 Senti Biosciences, Inc. Immunothérapie anticancéreuse combinatoire
WO2022077464A1 (fr) * 2020-10-16 2022-04-21 Apple Inc. Système et procédé de suivi de faisceau rapide dans un système de communication sans fil à haute fréquence
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
PE20250846A1 (es) 2020-12-31 2025-03-21 Immatics Us Inc Polipeptidos cd8, composiciones y metodos de uso de estos
BR112023022975A2 (pt) 2021-05-05 2024-01-23 Immatics Biotechnologies Gmbh Polipeptídeos de ligação ao antígeno bma031 melhorados
MX2024003142A (es) * 2021-09-17 2024-04-10 Univ Montreal Antigenos especificos de tumores novedosos para el cancer colorrectal y usos de estos.
EP4469162A1 (fr) 2022-01-25 2024-12-04 Ervimmune Nouvelle méthode d'identification d'épitopes dérivés d'herv
IL316515A (en) 2022-04-28 2024-12-01 Immatics Us Inc Membrane-bound IL15 CD8 proteins, cells, compositions and methods for their use
EP4514821A1 (fr) 2022-04-28 2025-03-05 Immatics US, Inc. Polypeptides d'il-12, polypeptides d'il-15, polypeptides d'il-18, polypeptides de cd8, compositions et leurs procédés d'utilisation
EP4514834A1 (fr) 2022-04-28 2025-03-05 Immatics US, Inc. Polypeptides récepteurs de tgfbêta négatifs dominants, polypeptides cd8, cellules, compositions et leurs méthodes d'utilisation
US20230355678A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
CN120712104A (zh) * 2022-10-14 2025-09-26 广东天科雅生物医药科技有限公司 针对神经胶质瘤的肽疫苗及其用途
WO2025096649A1 (fr) 2023-11-01 2025-05-08 Immatics US, Inc. Il-15 liée à une membrane, polypeptides de cd8, cellules, compositions et leurs procédés d'utilisation
WO2025211983A1 (fr) * 2024-04-05 2025-10-09 Общество с ограниченной ответственностью "Альбоген" Peptides avec activité antitumorale

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
DK171727B1 (da) 1978-12-22 1997-04-14 Biogen Inc Rekombinante hepatitis B virus DNA-molekyler, værtsorganismer transformeret hermed, HBV-antigenspecifikke polypeptider, DNA-sekvenser kodende for HBV-antigenspecifikke polypeptider, metoder til påvisning af hepatitis B virus-antistoffer, metoder til fremstilling af nævnte DNA-molekyler, fremgangsmåder til fremstilling af nævnte polypeptider og midler til påvisning af HBV-infektion
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
DE69420137T2 (de) 1993-06-03 1999-12-23 Therapeutic Antibodies, Inc. Herstellung von antikörperfragmenten
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
CA2243235C (fr) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapie utilisant des lymphocytes t cytotoxiques (ctl)
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US5759812A (en) 1996-11-15 1998-06-02 Incyte Pharmaceuticals, Inc. Human selenium-binding protein
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1109568A4 (fr) 1998-09-04 2002-05-08 Ludwig Inst Cancer Res Peptide antigenique code par un autre cadre de lecture ouvert de facteur stimulant la proliferation des macrophages
US7504490B1 (en) * 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
EP1001022A1 (fr) 1998-10-16 2000-05-17 Boehringer Ingelheim International GmbH CAMEL, un produit de translation alternative d'antigène tumoraux LAGE-1
JP4748908B2 (ja) 1999-09-10 2011-08-17 ザ・ユニバーシティ・オブ・シドニー ジペプチジルペプチダーゼ
IL151860A0 (en) 2000-03-27 2003-04-10 Technion Res & Dev Foundation Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
AU7524601A (en) 2000-06-05 2001-12-17 Sunol Molecular Corp T cell receptor fusions and conjugates and methods of use thereof
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP1485075A4 (fr) 2002-02-20 2006-04-26 Dyax Corp Ligands de liaison au complexe mhc-peptide
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
AU2003276403B2 (en) 2002-11-09 2010-04-15 Adaptimmune Limited T cell receptor display
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
DE102005041616B4 (de) * 2005-09-01 2011-03-17 Johannes-Gutenberg-Universität Mainz Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen
EP1806358B1 (fr) 2005-09-05 2010-03-17 Immatics Biotechnologies GmbH Peptides associés aux tumeurs se liant étroitement aux molécules du système majeur d'histocompatibilité (HLA) de classe II
US8871211B2 (en) 2006-09-28 2014-10-28 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
DE602008000891D1 (de) 2008-04-30 2010-05-12 Immatics Biotechnologies Gmbh Neuartige Formulierungen von Tumor-assoziierten Peptiden, welche an menschliche Leukozytenantigene der Klasse I oder II für Impfungen binden
RS53872B2 (sr) 2008-05-14 2018-06-29 Immatics Biotechnologies Gmbh Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana
US9840695B2 (en) 2009-04-28 2017-12-12 Agriculture Victoria Services Pty Ltd Plant technology
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
WO2012056407A1 (fr) 2010-10-26 2012-05-03 Technion Research & Development Foundation Ltd. Anticorps qui se lient à des ligands de récepteurs de lymphocytes t solubles
WO2013057586A1 (fr) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions et procédés de production de récepteurs solubles des lymphocytes t
EP2917388B1 (fr) 2012-11-08 2016-10-05 Roche Diagnostics GmbH Acides nucléiques codant pour des polypeptides chimériques pour criblage de banque
US9943570B2 (en) 2012-12-21 2018-04-17 Technische Universitat Dresden Manipulation of hairy and enhancer of split 3 (Hes3) and its regulators/mediators as an anti-cancer strategy
EP2808392A1 (fr) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamères et utilisation de ces aptamères dans le diagnostic et le traitement du cancer
TWI777194B (zh) 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（一）
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201411037D0 (en) * 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
RU2719033C2 (ru) * 2015-04-23 2020-04-16 Нантомикс, Ллс Способ получения фармацевтического агента для иммунотерапии рака
GB201515321D0 (en) 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201517538D0 (en) 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
GB201520579D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
BR112018070873A2 (pt) 2016-04-21 2019-02-05 Immatics Biotechnologies Gmbh imunoterapia contra melanoma e outros cânceres
TWI796299B (zh) * 2016-08-26 2023-03-21 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
EP3679065A4 (fr) * 2017-09-06 2021-05-19 California Institute of Technology Signalisation et récepteurs bifonctionnels présentant des antigènes (sabr)
FR3070845B1 (fr) 2017-09-13 2021-07-30 Oreal Outil de mesure d'au moins une propriete d'une surface corporelle et procede de mesure associe
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten

Also Published As

Publication number Publication date
US20210052654A1 (en) 2021-02-25
US20200206268A1 (en) 2020-07-02
US20200155605A1 (en) 2020-05-21
US20230263830A1 (en) 2023-08-24
EA202091754A1 (ru) 2021-02-08
US20200323907A1 (en) 2020-10-15
TWI776160B (zh) 2022-09-01
US10869891B2 (en) 2020-12-22
US11369636B2 (en) 2022-06-28
US20200038448A1 (en) 2020-02-06
US20210401892A1 (en) 2021-12-30
US20210052651A1 (en) 2021-02-25
US11033585B2 (en) 2021-06-15
AU2022202512B2 (en) 2023-12-14
JP7384884B2 (ja) 2023-11-21
US11020434B2 (en) 2021-06-01
EP4321529A3 (fr) 2024-07-17
US10780123B2 (en) 2020-09-22
US10709737B2 (en) 2020-07-14
US11179418B2 (en) 2021-11-23
US11779606B2 (en) 2023-10-10
US11033583B2 (en) 2021-06-15
US10695376B2 (en) 2020-06-30
US20200323916A1 (en) 2020-10-15
TWI837747B (zh) 2024-04-01
US20200155604A1 (en) 2020-05-21
CL2020002123A1 (es) 2020-10-16
US11077142B2 (en) 2021-08-03
US20210338734A1 (en) 2021-11-04
US20200297771A1 (en) 2020-09-24
US20200306308A1 (en) 2020-10-01
US20200323911A1 (en) 2020-10-15
US20190255112A1 (en) 2019-08-22
US11951132B2 (en) 2024-04-09
US20200323913A1 (en) 2020-10-15
SG11202006630RA (en) 2020-09-29
US20230241115A1 (en) 2023-08-03
CO2020009869A2 (es) 2020-08-21
BR122020014377A8 (pt) 2023-03-28
US20200108097A1 (en) 2020-04-09
US20200323919A1 (en) 2020-10-15
US20200038447A1 (en) 2020-02-06
US11103535B2 (en) 2021-08-31
US11052113B2 (en) 2021-07-06
US20200306305A1 (en) 2020-10-01
US10874695B2 (en) 2020-12-29
US20200179453A1 (en) 2020-06-11
US20210069251A1 (en) 2021-03-11
US10874696B2 (en) 2020-12-29
US20210260120A1 (en) 2021-08-26
US20230241114A1 (en) 2023-08-03
US10780124B2 (en) 2020-09-22
US11918607B2 (en) 2024-03-05
US11026977B2 (en) 2021-06-08
BR112020014272A2 (pt) 2020-12-15
US11013768B2 (en) 2021-05-25
US20210137985A1 (en) 2021-05-13
US20200268800A1 (en) 2020-08-27
JP2022050398A (ja) 2022-03-30
US11013769B2 (en) 2021-05-25
US20200268799A1 (en) 2020-08-27
US11141437B2 (en) 2021-10-12
US10993964B2 (en) 2021-05-04
US10888584B2 (en) 2021-01-12
US20200323914A1 (en) 2020-10-15
US20200268798A1 (en) 2020-08-27
US11052114B2 (en) 2021-07-06
BR122020014377A2 (pt) 2020-12-29
AU2020204568B2 (en) 2022-02-03
US20210213064A1 (en) 2021-07-15
EA202091833A1 (ru) 2020-11-25
TW202246307A (zh) 2022-12-01
US10709738B2 (en) 2020-07-14
US10869895B2 (en) 2020-12-22
US20210137986A1 (en) 2021-05-13
US20230241108A1 (en) 2023-08-03
US20190255113A1 (en) 2019-08-22
US20230285460A1 (en) 2023-09-14
PE20210376A1 (es) 2021-03-02
US20190255164A1 (en) 2019-08-22
US10799537B2 (en) 2020-10-13
US10695373B2 (en) 2020-06-30
MX2020007767A (es) 2020-10-12
US10869893B2 (en) 2020-12-22
US20200261504A1 (en) 2020-08-20
CL2021000842A1 (es) 2021-09-03
US10751369B2 (en) 2020-08-25
US20200038446A1 (en) 2020-02-06
US10898519B2 (en) 2021-01-26
PH12020551295A1 (en) 2021-07-12
US20200323909A1 (en) 2020-10-15
US20200323906A1 (en) 2020-10-15
US20200297770A1 (en) 2020-09-24
US10888585B2 (en) 2021-01-12
US10702553B2 (en) 2020-07-07
US11058727B2 (en) 2021-07-13
US20210060077A1 (en) 2021-03-04
US20210060074A1 (en) 2021-03-04
AU2019225879A1 (en) 2020-07-09
US20200163996A1 (en) 2020-05-28
US20200171091A1 (en) 2020-06-04
KR20200116527A (ko) 2020-10-12
US20200085873A1 (en) 2020-03-19
US20200306311A1 (en) 2020-10-01
TW201936630A (zh) 2019-09-16
US20200323918A1 (en) 2020-10-15
US10695374B2 (en) 2020-06-30
US10792308B2 (en) 2020-10-06
TW202043257A (zh) 2020-12-01
US11065279B2 (en) 2021-07-20
US10905719B2 (en) 2021-02-02
US10869890B2 (en) 2020-12-22
AU2022202522A1 (en) 2022-05-12
US20230241113A1 (en) 2023-08-03
US20220000922A1 (en) 2022-01-06
AU2022202520A1 (en) 2022-05-12
IL276845A (en) 2020-10-29
US10869892B2 (en) 2020-12-22
CN114040921A (zh) 2022-02-11
WO2019162110A1 (fr) 2019-08-29
US10888582B2 (en) 2021-01-12
US10869896B2 (en) 2020-12-22
PE20211300A1 (es) 2021-07-20
US10772915B2 (en) 2020-09-15
CA3086916A1 (fr) 2019-08-29
US11147839B2 (en) 2021-10-19
US20210052653A1 (en) 2021-02-25
US10780122B2 (en) 2020-09-22
JP2025000689A (ja) 2025-01-07
US10894064B2 (en) 2021-01-19
MY200985A (en) 2024-01-27
US20200297772A1 (en) 2020-09-24
US11154576B2 (en) 2021-10-26
US20210113619A1 (en) 2021-04-22
US20230241110A1 (en) 2023-08-03
US10813953B2 (en) 2020-10-27
US10993962B2 (en) 2021-05-04
AU2019225879B2 (en) 2022-01-27
US20200261505A1 (en) 2020-08-20
JP7536642B2 (ja) 2024-08-20
US10869894B2 (en) 2020-12-22
US20190255110A1 (en) 2019-08-22
US20200261506A1 (en) 2020-08-20
US20210244765A1 (en) 2021-08-12
US20200323910A1 (en) 2020-10-15
AU2022202512A1 (en) 2022-05-12
JP2024099580A (ja) 2024-07-25
US20200222465A1 (en) 2020-07-16
US20210145886A1 (en) 2021-05-20
KR20200123134A (ko) 2020-10-28
US20230241112A1 (en) 2023-08-03
US10888586B2 (en) 2021-01-12
US11376281B2 (en) 2022-07-05
EP4321529A2 (fr) 2024-02-14
US20210330708A1 (en) 2021-10-28
JP2021514178A (ja) 2021-06-10
US10709736B2 (en) 2020-07-14
US11020433B2 (en) 2021-06-01
US11013766B2 (en) 2021-05-25
US20200179454A1 (en) 2020-06-11
US11147838B2 (en) 2021-10-19
US20230285462A1 (en) 2023-09-14
US11801264B2 (en) 2023-10-31
US20210145888A1 (en) 2021-05-20
US20230233612A1 (en) 2023-07-27
US20200360433A1 (en) 2020-11-19
US20200323915A1 (en) 2020-10-15
US20210100845A1 (en) 2021-04-08
DE102018107224A1 (de) 2019-08-22
US10898518B2 (en) 2021-01-26
US11197892B2 (en) 2021-12-14
US20210052652A1 (en) 2021-02-25
AU2022202522B2 (en) 2023-12-21
MX2020007808A (es) 2020-10-05
US10695375B2 (en) 2020-06-30
US20200197441A1 (en) 2020-06-25
US20210338735A1 (en) 2021-11-04
SG10202010171VA (en) 2020-11-27
US20230241109A1 (en) 2023-08-03
AU2020204568A1 (en) 2020-07-30
IL276987A (en) 2020-10-29
US10695377B2 (en) 2020-06-30
US10905720B2 (en) 2021-02-02
US20210145887A1 (en) 2021-05-20
US20200085874A1 (en) 2020-03-19
JP7732024B2 (ja) 2025-09-01
EP3755708A1 (fr) 2020-12-30
US20210060078A1 (en) 2021-03-04
CL2020002387A1 (es) 2021-02-12
US20200093862A1 (en) 2020-03-26
US20230285461A1 (en) 2023-09-14
CL2021000841A1 (es) 2021-09-03
CR20200365A (es) 2020-09-18
US11040069B2 (en) 2021-06-22
US11357797B2 (en) 2022-06-14
US10792307B2 (en) 2020-10-06
US10888583B2 (en) 2021-01-12

Similar Documents

Publication Publication Date Title
MA42494A (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre divers cancers
MA41805A (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre diverses tumeurs
MA50542A (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés en immunothérapie contre le cancer ovarien épithélial et d'autres cancers
MA43690A (fr) Peptides, combinaison de peptides et médicaments à base de cellules destinés à être utilisés en immunothérapie contre le cancer de la vessie et d'autres cancers
MA49122A (fr) Peptides et combinaisons de peptides destinés à être utilisés en immunothérapie anticancéreuse
MA51531A (fr) Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l' oesophage et d'autres cancers
MA44228A (fr) Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre le lymphome non hodgkinien et d'autres cancers
MA45073A (fr) Nouveaux peptides, combinaison de peptides et d'échafaudages destinés à être utilisés dans le traitement immunothérapeutique de divers cancers
MA43399A (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre la cll et d'autres cancers
MA50925A (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
PT3423105T (pt) Conjugados de anticorpo-fármaco à base de eribulina e métodos de utilização
EP3452597A4 (fr) Procédés et compositions d'agents biologiquement actifs
EP3268809A4 (fr) Formulation de matériau de support et procédés de fabrication d'additifs à l'aide de celle-ci
EP3299028A4 (fr) Combinaison de peptide d'antigène wt1 et d'immunomodulateur
MA53033A (fr) Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancers
SG11202100214SA (en) Antagonists of t2r54 and compositions and uses thereof
MA47367A (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
MA53326A (fr) Immunothérapie à l'aide de peptides restreints par b*07 et combinaison de peptides contre des cancers et méthodes associées
JP2018172409A5 (ja) １５−ｈｅｐｅを含む組成物および同組成物を使用する方法
IL283787A (en) Herboxidiene antibody-drug conjugates and methods of use
SI3793586T1 (sl) Različice receptorja za topni komplement tipa 1 in njihova uporaba
MA49123A (fr) Peptides et combinaison de peptides à utiliser en immunothérapie contre les leucémies et d'autres cancers
EP4029944A4 (fr) Combinaison de plasmides et son application dans la préparation de cellules immunitaires modifiées
IL277404A (en) C3-binding substances and methods of using them
MA53641A (fr) Peptides restreints b*44 destinés à être utilisés en immunothérapie contre des cancers et méthodes associées